Globe Newswire10.04.19
Conformis Inc. announced today that Paul Weiner, the company's chief financial officer (CFO), is leaving on Oct. 18 to become the CFO at a privately-owned business in Fremont, Calif.
As a result, the company’s Board of Directors has begun a search to appoint a successor. Weiner has agreed to work with Conformis as an advisor to help achieve a smooth transition.
CEO Mark Augusti said: “Paul has been our CFO since 2014 and was instrumental in taking Conformis public. He has been a valued member of the management team and has made a huge contribution to the success of the business. On behalf of the company and the Board, I would like to thank him for his work and contributions over many years.”
Weiner said: “I have been privileged to work with an outstanding team during my tenure at Conformis. I thank the board and the leadership team for their support and enjoyed my interactions with all the employees and business partners. I leave the company both financially and operationally strong at an exciting time with the recently announced development, license, and distribution agreements with Stryker. I am confident that Conformis will continue to deliver value for shareholders and customers alike.”
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a line of customized knee and hip implants and customized pre-sterilized, single-use instruments delivered to the hospital. In clinical studies, Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.
As a result, the company’s Board of Directors has begun a search to appoint a successor. Weiner has agreed to work with Conformis as an advisor to help achieve a smooth transition.
CEO Mark Augusti said: “Paul has been our CFO since 2014 and was instrumental in taking Conformis public. He has been a valued member of the management team and has made a huge contribution to the success of the business. On behalf of the company and the Board, I would like to thank him for his work and contributions over many years.”
Weiner said: “I have been privileged to work with an outstanding team during my tenure at Conformis. I thank the board and the leadership team for their support and enjoyed my interactions with all the employees and business partners. I leave the company both financially and operationally strong at an exciting time with the recently announced development, license, and distribution agreements with Stryker. I am confident that Conformis will continue to deliver value for shareholders and customers alike.”
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a line of customized knee and hip implants and customized pre-sterilized, single-use instruments delivered to the hospital. In clinical studies, Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover customized implants and customized patient-specific instrumentation for all major joints.